Gynecologic Oncology

Article	Citations
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer	101
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery	96
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)	94
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)	88
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes	79
Redefining readmissions in gynecologic cancer: readmissions resulting in hospital-to-hospice transitions may represent high value care	78
Stage IV gynecologic cancers patients who subsequently died from disease: lessons learned from their health care journey	74
Sentinel lymph node procedures in endometrial cancer: an international multicenter experience	74
The impact of the SARS-COV2 pandemic on the delivery of chemotherapy for gynecologic cancer at a tertiary care institution in the United States epicenter	70
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne	62
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)	60
Neoadjuvant chemotherapy with interval debulking surgery versus chemotherapy alone for advanced epithelial ovarian cancer	59
Outcomes of splenectomy during primary cytoreductive surgery in ovarian cancer	59
Perioperative outcomes in obese women with uterine cancer	57
Recurrent ovarian cancer: maintenance treatment with PARP inhibitors in clinical practice	56
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)	55
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)	54
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)	53
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)	52
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203	52
Impact of surgeon type and rurality on treatment and survival of ovarian cancer patients	51
Hot or not: defining trophoblast PD-L1 expression and lymphohistiocytic density in gestational trophoblastic neoplasia	51
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)	49
Clinical outcomes and cost associated with HRD biomarker guided first line maintenance therapy in advanced ovarian cancer	47
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)	47

Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)	46
Comparison of solid tumor mutations under the targeted agent and profiling utilization registry (TAPUR) study: how do gynecologic cancers compare with others?	45
Determining the optimal adjuvant therapy strategy in uterine leiomyosarcoma	45
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)	45
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)	44
Disparities in access to high volume surgeons within high volume hospitals for hysterectomy	43
Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer	43
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)	43
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)	43
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)	41
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce	41
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)	41
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)	41
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)	40
Assessing somatic mutations in matched biospecimens from patients with serous ovarian cancer	40
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)	40
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)	38
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)	38
Comprehensive genomic profiling (CGP) via peripheral blood liquid biopsies identifies therapeutically relevant genomic alterations in tubo-ovarian and peritoneal cancer	37
Quality of oncologic care and outcomes of patients with endometrial cancer managed at minority-serving hospitals	36
Ketogenic Diet Promotes Epithelial Ovarian Cancer Progression and Alters Tumor Gene Expression in-vivo (104)	36
Metastatic site-specific prognosis of women with stage IVB cervical cancer (345)	36
Telemedicine and gynecologic oncology: caring for patients remotely during a global pandemic	36
Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma (173)	35
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167)	34
Professional fulfillment and burnout among physicians at a large NCI-designated Comprehensive Cancer Center	34
Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)	34
Uptake and outcomes of sentinel lymph node mapping in women with atypical endometrial hyperplasia	34
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis	33
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)	33
Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021,	32
Workplace bullying, harassment and microaggressions: the results of a Women of Gynecologic Oncology (WGO) survey	32
A conceptual model of vulnerability to care delay among women at risk for endometrial cancer	31
The clinical utility of the Khorana score in determining risk for venous thromboembolism in patients with gynecologic cancer	31
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer	31
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC)	31
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group	30
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial	30
Defining “enlarged” sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?	30
Publication trends focused on palliative and end-of-life care for gynecologic malignancies	30
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA)	29
Patients with lower health literacy are less likely to be identified as eligible for hereditary cancer genetic testing by a digital risk stratification tool: An urban academic gynecologic oncology cli	29
Uterine cancer among Asian Americans: Disparities & clinical characteristics and disease presentations	29
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations	29
RE1 transcription factor is decreased in endometrial cancer	29
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer	29
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer	29
Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers	29
Peritoneal washing analysis in endometrial cancer: Does somatic mutation detection with panel sequencing build upon traditional cytologic analysis?	29
The outcome of waiting for radiotherapy in locally advanced cervical cancer	28

Spatial RNA sequencing supports programmed death ligand 2 (PD-L2) as a potential immunotherapy target in high-grade serous ovarian carcinoma	28
The implementation of an electronic symptom management system to monitor the severity of symptoms in gynecologic oncology patients initiating chemotherapy: A multicenter evaluation	28
Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure	28
Themes, perspectives, and educational quality of content related to Pap smears on TikTok and YouTube	28
The Doc versus the Bot: A pilot study to assess the quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology	27
Defects in mismatch repair promote disease character likeness amongst Black and White women with endometrial cancer	27
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices	27
The use of pedometers to assess patient ambulation following gynecologic oncology surgery: A prospective observational study	27
COPANIRA: Phase Ib trial of copanlisib (PI3K inhibitor) and niraparib (PARP inhibitor) in recurrent ovarian and endometrial cancer	27
Accuracy of patient-reported gynecologic cancer diagnoses and procedures at a large academic medical center	27
Outcomes among patients with chronic kidney disease undergoing HIPEC for ovarian cancer	27
Oncologic outcomes and adverse events with immunotherapy treatment among frail patients with gynecologic cancers	27
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125	26
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor	26
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma	26
Editorial board	26
Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III tria	26
Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission	26
Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program	25
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials	25
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs	25
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility	25
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer – An NRG/GOG study	25
Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study fr	25
What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice?	25
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903	25
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial	25
Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study	24
Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320)	24
Trial in progress: A phase two trial of nirogacestat, a gamma-secretase inhibitor, in patients with recurrent ovarian granulosa cell tumors (NCT05348356) (1284)	24
Profiling the immune landscape in mucinous ovarian carcinoma	24
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)	24
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo	24
Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer	24
CRABP2 – A novel biomarker for high-risk endometrial cancer	24
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement	23
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies	23
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study	23
Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends	23
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial	23
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study	23
Disparities in ovarian cancer treatment and overall survival according to race: An update	23
Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis	23
Platinum refractory advanced stage ovarian clear cell carcinoma: time to reconsider primary therapy?	22
Novel therapy in endometrial cancer: How much will we pay?	22
Endometrial cancer recurrence after the use of an intrauterine manipulator during laparoscopic surgery: A retrospective cohort study (1216)	22
Obesity-driven microbial and metabolic changes with cytotoxic chemotherapy in the LKB1fl/flp53fl/fl genetically engineered mouse model of endometrioid endometrial cancer	22
Editorial board	22
Characterization and comparison of pelvic mass risk assessment by gynecologists and PCPs to ROMA	22
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas	22
Cervical Cancer Disparities in the American Indian/Alaska Native Population: Are Prevention Tools Being Utilized? (108)	22
Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative	22
Obesity-related cancers disproportionately affect women compared to men in the United States (399)	22
Analyses of DNA repair protein expression in BRCA1 mutant patient-derived xenografts	22
Social precarity as a novel framework for addressing psychosocial needs of patients with gynecologic cancers (2227)	22
Editorial board	22
Utilizing the KELIM score and the chemo-response score to predict chemosensitivity in ovarian cancer (1212)	22
Editorial board	22
Thoracic epidural analgesia in Gynecologic Oncology ERAS: A waste of time or time to consider it as a standard of care? (2162)	22
The rising incidence of sex cord stromal ovarian tumors in the US: Who is most at risk? (442)	22
Distinct T cell receptor diversity and integrative analyses of clinically defined high-grade serous ovarian cancer	21
Utility of lymphadenectomy in mucinous ovarian carcinoma	21
Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium (029)	21
Lived experience of women diagnosed with a gynecologic cancer in the height of the COVID-19 pandemic in New York City (508)	21
Effect of treatment sequence on mortality in advanced-stage endometrial cancer	21
Sentinel lymph node biopsy compared with systematic lymphadenectomy in patients with uterine carcinosarcoma (536)	21
The impact of abortion restrictions on pregnant individuals with cancer in the United States: A statistical model (013)	21
Telemedicine patient satisfaction metrics and methods of recurrence detection for gynecologic cancer patients throughout the initial year of the COVID-19 pandemic (515)	21
Frequency of homologous recombination associated gene mutations in Japanese patients with ovarian cancer	21
Geographic disparities in the United States gynecologic oncology workforce: Cancer care inequities and the paradox of more docs (014)	21
Foreword	20
Molecular targets and prognosis for uterine cancer: What is the role of mutations of unknown significance? (1262)	20
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study	20
Widening cancer care disparities in the adoption of telemedicine during COVID 19: who is left behind?	20
Early detection of endometrial cancer	20
Silencing ROR2 inhibits metastatic behavior of ovarian cancer cells	20
Surgical universal euglycemic attainment during recovery (SUGAR) initiative: Sweet results through quality improvement (286)	20
Response to Letter to the Editor, Gilks et al.	20
The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies	20
Transcriptomic immune profiling: a precision path forward for immunotherapy in patients with cervical cancer?	20

Phase II trial of eribulin in advanced/recurrent cervical cancer	19
Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovari	19
Response to Alexandre Andre B A da Costa et al.	19
The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial	19
Frequency of actionable germline mutations identified through tumor next generation sequencing in a gynecologic cancer cohort (394)	19
Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies	19
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification	19
Variation in cervical cancer screening test utilization and results in a United States-based program	19
Health care services burden in ovarian cancer patients receiving PARP inhibitor maintenance treatment (377)	19
Investigation of perturbation of DNMT and TET enzymes in endometrial cancer (308)	19
Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab f	19
Co-expression of PD-L1 and DDR2 in cervical cancer	19
Postoperative management and outcomes before and after closure of a women's health specialty unit at a tertiary care facility	19
Cancer center case volume is associated with differences in the effectiveness of neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer	18
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global,	18
Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328	18
Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings:	18
Disease progression, survival, and molecular disparities among Black and White patients with endometrioid endometrial carcinoma in real-world registries and legacy NRG oncology phase III trials	18
Characteristics and factors associated with mortality among cervical cancer patients undergoing palliative care	18
Gamma secretase inhibitors, in combination with cytotoxic agents, decrease migration and invasion of uterine leiomyosarcoma	18
Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate, trastuzumab deruxtecan	18
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants	18
3D organoid models for predicting drug response in platinum-sensitive, high-grade serous ovarian cancer	18
Progression-free and overall survival of sequential platinum, taxane, and bevacizumab followed by immunotherapy may be equivalent to concurrent chemotherapy and immunotherapy among patients with recur	17
Frailty does not completely explain racial disparities in postoperative outcomes after ovarian cancer debulking	17
Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes	17
Assessing the readability of online health information regarding treatment modalities for gynecologic cancer patients	17
Financial toxicity among gynecologic oncology surgical patients	17
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer	17
Exploring the mechanisms of resistance to trastuzumab-deruxtecan in endometrial cancer cells	17
Patterns of recurrence and outcomes in vulvar extramammary Paget's disease	17
Feasibility of laparoscopic visceral-peritoneal debulking among patients with stage III–IV ovarian cancer: The ULTRA-LAP Pilot Trial	17
High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial	17
Overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma (LBA 5)	16
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021	16
Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Nor	16
Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis	16
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2, ≤50 % invasive endometrial cancer: Candidates for adjuvant therapy	16
Eliminating racial disparities in endometrial cancer clinical trial enrollment in the Deep South: a pathway to equity	16
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPE	16
System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review	16
Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia rece	16
Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists	16
Cognitive outcomes after premenopausal risk-reducing Salpingo-oophorectomy: The role of hormone therapy	16
Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer	16
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression	16
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning	16
Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic	16
Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwa	16
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival	16
Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171)	16
Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer	16
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center	16
From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?	16
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma	16
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer	15
Utility of germline multi-gene panel testing in patients with endometrial cancer	15
Molecular diversity in uterine carcinosarcoma: Beyond TP53	15
TERT promoter mutations and gene amplification in endometrial cancer	15
Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy	15
Cervical adenocarcinoma: Factors and outcomes in early-stage patients	15
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist	15
Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study	15
SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (LBA	15
An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial	15
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis	15
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial	15
Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin- expressing cancers (314)	15
Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/	15
Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study	15
Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081	15
Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer	15
Impact of COVID-19 on missed diagnoses of uterine cancer: Who is most affected?	14
Immunotherapy: Is it all about timing?	14
Gynecologic oncology patients with severe mental illness diagnosis are more likely to experience adverse outcomes during hospitalizations for cancer-directed treatment	14
Pre-clinical investigation of a novel investigational new drug, SHetA2, for the treatment of vulvar cancer	14
Ovarian cancer patients demonstrating durable clinical benefit from neoadjuvant chemo-immunotherapy are associated with significant reductions in tumor-infiltrating CCR8+ regulatory T-cells	14
Editorial Board	14
Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy	14
The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer	14
Intra-peritoneal CAR-T cell therapy shows promising results in a murine model of epithelial ovarian cancer (313)	14
Medical decision making from the perspective of the gynecologic oncology patient	14
Characteristics of mismatch repair deficient endometrial cancer in a diverse cohort	14
The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer	14
Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial	14
Practice patterns and clinical outcomes in women with gynecologic malignancies who refuse blood products	14
Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database	14
Implementation of automated social determinants of health screening in gynecologic oncology: A pilot study	14
Interim post-progression data and updated survival in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO	14
p53 functional status is associated with survival among high-grade serous ovarian cancer patients with copy number signature one	14
Microenvironment cell populations are associated with clinical outcomes in high-grade serous ovarian cancer	14
Phase II basket study of disitamab vedotin among patients with previously-treated, locally advanced unresectable or metastatic solid tumors that express HER2: Ovarian and endometrial cancer cohorts (D	14
Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer – a nationwide population-based study	14
Effect of preoperative cervical conization before hysterectomy on survival and recurrence of patients with cervical cancer: A systematic review and meta-analysis	14
Screening for endometrial disease: Analyzing risk factors for abnormal endometrial pathology in a high-risk population	14